DeutschNewstral
Article
jdsupra.com on 2016-08-11 02:33
AbbVie Sues Amgen On 10 Of 100 Humira Patents
Related news
- AbbVie Sues Amgen to Prevent Launch of Humira Biosimilarjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilarpacbiztimes.com
- PTAB Denies Challenge Of Abbvie Humira Patentsjdsupra.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilarsjdsupra.com
- PAmgen settles with AbbVie over Humira biosimilar litigationpacbiztimes.com
- Coherus Settles with AbbVie, and Sues Amgen, Over Adalimumab Biosimilars (Updated)jdsupra.com
- California Sues AbbVie Over Alleged Kickbacks for HUMIRAjdsupra.com
AbbVie sues to fend off copy of Humira drugdailyherald.com- HUMIRA® Biosimilar Update -- Settlement in AbbVie v. Amgen Case Announced and AbbVie v. Boehringer Ingelheim Litigation Beginsjdsupra.com
- New BPCIA Litigaton: AbbVie Sues Boehringer Ingelheim Regarding Proposed Biosimilar to Humira (adalimumab)jdsupra.com
- UK Court Invalidates AbbVie HUMIRA Patentsjdsupra.com
- AbbVie Licenses Humira® (Adalimumab) Patents to Mylanjdsupra.com
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- PAmgen launches Humira biosimilar in Europepacbiztimes.com
- PFDA approves Amgen biosimilar of AbbVie’s Humirapacbiztimes.com
- LHumira Beating Market by Excellent Revenue growth | Eisai, Amgen, AbbVieliverpoolstudentmedia.com
- Amgen and AbbVie Settle Adalimumab BPCIA Litigationjdsupra.com
AbbVie protects blockbuster drug Humira for 5 years through settlementChicago Tribune
The Strategies AbbVie Employed to Protect Humira From Copycatswsj.com- New BPCIA Complaint: Amgen Sues Pfizer over Proposed Filgrastim Biosimilarjdsupra.com